Lincoln Pharmaceuticals Sees Profit Surge and Sets Ambitious Growth Targets

Lincoln Pharmaceuticals announces a 17% growth in net profit for Q1 FY26, reaching Rs 27.70 crore. Total income rose by 7.3% to Rs 169.34 crore. The company aims for Rs 1,000 crore within three years through market expansion and high-value products, backed by strong segment performance and a new manufacturing plant.

Lincoln Pharmaceuticals reported a 17 per cent increase in net profit for the first quarter of FY26, achieving Rs 27.70 crore. The company's total income grew by 7.3 per cent, reaching Rs 169.34 crore. This positive performance was highlighted in a statement released by the company on Thursday.

The EBITDA for Q1 FY26 was Rs 39.08 crore, marking a 17.92 per cent year-on-year growth. Lincoln Pharmaceuticals has set an ambitious target to reach a revenue of Rs 1,000 crore within the next three years. Managing Director Mahendra Patel attributed this goal to the company's expansion into high-value product lines and new markets.

The company's shares increased by 8.47 per cent, closing at Rs 576.90 on the BSE. Lincoln Pharmaceuticals also inaugurated its bulk drug manufacturing plant during the quarter, investing Rs 4 crore from internal accruals, and received 10 product approvals.